anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Oral hygienic products containing fennel seed essential oil are provided, which oral hygienic products emit fresh mint perfume, give freshness, and have enlarged residual rate within a mouth, so that they can substitute synthetic perfume. The oral hygienic products contain 0.005 to 3 wt.% of essential oil of fennel seed(Foeniculum vulgare MILL.) as an effective component, wherein the oral hygienic products further contain 0.001 to 0.1 wt.% of a synthetic sterilizing agent; the essential oil of fennel seed(Foeniculum vulgare MILL.) is obtained by using vacuum distillation or supercritical fluid extraction; the vacuum distillation is carried out by distilling fennel seed(Foeniculum vulgare MILL.) powder in water under pressure of 10-2 to 10-3 torr and temperature of 40 to 60 deg. C for 1 to 4 hours; the supercritical fluid extraction is carried out by distilling fennel seed(Foeniculum vulgare MILL.) in an extractor under pressure of 80 to 100 atmospheres and temperature of 30 to 50 deg. C for 1 to 3 hours, or under pressure of 160 to 180 atmospheres and temperature of 30 to 50 deg. C for 30 minutes to 1 hour; and the oral hygienic product is selected from liquid mouse washer, tooth paste, falth tooth washer, chewing gum and oral paste.
Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system characterized by autoimmune-mediated damage to oligodendrocytes and subsequent myelin destruction. Clinical implications: Clinically, the disease presents with many symptoms, often evolving over time. The insidious onset of MS often manifests with non-specific symptoms (prodromal phase), which may precede a clinical diagnosis by several years. Among them, headache is a prominent early indicator, affecting a significant number of MS patients (50-60%). Results: Headache manifests as migraine or tension-type headache with a clear female predilection (female-male ratio 2-3:1). Additionally, some disease-modifying therapies in MS can also induce headache. For instance, teriflunomide, interferons, ponesimod, alemtuzumab and cladribine are associated with an increased incidence of headache. Conclusions: The present review analyzed the literature data on the relationship between headache and MS to provide clinicians with valuable insights for optimized patient management and the therapeutic decision-making process.
Rare cases of liver failure, some leading to death or liver transplant, have occurred with the use of Terbinafine Hydrochloride Tablets for the treatment of onychomycosis in individuals with and without pre-existing liver disease.

In the majority of liver cases reported in association with terbinafine hydrochloride use, the patients had serious underlying systemic conditions and an uncertain causal association with terbinafine hydrochloride. The severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease (see PRECAUTIONS). Treatment with Terbinafine Hydrochloride Tablets should be discontinued if biochemical or clinical evidence of liver injury develops (see PRECAUTIONS below).

There have been isolated reports of serious skin reactions (e.g., Stevens-Johnson Syndrome and toxic epidermal necrolysis). If progressive skin rash occurs, treatment with terbinafine hydrochloride should be discontinued.
Standard physiotherapy stroke rehabilitation which includes training for regaining walking as well as other functional tasks, 3 - 5 days a week for 30-60 minutes per session until discharge (or to a maximum of 8 weeks). Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke.
The subjects in the control group go about their normal life for 10 weeks without any intervention. The control group is tested before and after the 10 week period.
INTRODUCTION: High horseshoe-shaped anal fistula (HHAF) is a complicated and challenging condition that presents considerable obstacles in treatment. We are presently investigating a novel surgical technique involving a combination of multi-incision and tube-dragging therapy, and laser closure (MITD-LaC) for the management of HHAF. Due to the current scarcity of rigorous evidence evaluating this approach, it is essential to perform a well-designed randomized controlled trial to compare the effectiveness of this new method with incision and thread-drawing therapy.
METHODS AND ANALYSIS: This trial is a prospective, randomized, controlled and interventional study. After preliminary screening of qualified outpatients, a total of 64 adult patients will be enrolled in the trial and randomly allocated to either the MITD-LaC group or the control group (n = 32 per group). These patients will receive either MITD-LaC or incision and thread-drawing therapy. The design aims to allow for a robust comparison between the two treatment modalities. The primary endpoint is the wound healing time, while secondary endpoints include postoperative anal pain at 1, 3, and 5 days (measured with visual analogue scale), fecal incontinence score within 30 days after operation (measured with Cleveland Clinic Florida incontinence score), and the occurrence of postoperative complications within 1 month after surgery, and quality of life up to six months postoperatively (evaluated by The Quality of Life in patients with Anal Fistula Questionnaire Score).
DISCUSSION: This study represents the first randomized controlled trial evaluating the short-term outcomes of MITD-LaC, thereby aiming to contribute high-quality evidence to guide clinical practice. Moreover, this trial incorporates comprehensive outcome measures assessing both subjective and objective dimensions. Because of this multidimensional assessment, MITD-LaC offers a promising potential for broader application in the treatment of HHAF. Consequently, obtaining more definitive and authoritative evidence through scientifically rigorous clinical trials is of utmost importance in further validating this treatment approach.
ETHICS AND DISSEMINATION: We have submitted the clinical study protocol to the Ethics Committee, and it has been approved under ethical approval number 2021-1036-111-01. The results of the trial will be disseminated through peer-reviewed academic journals and presentations at professional conferences.
REGISTRATION NUMBER: ChiCTR2100053556.
Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
The study objective is to characterize how sleep deficiency influences youth's ability to engage with, implement, and benefit from pain self-management intervention. The investigators will recruit a cohort of 80 youth, ages 12 to 17 years, with chronic musculoskeletal, head, or abdominal pain into a single arm trial conducted at one site. Assessments will occur at baseline, immediately after intervention, and repeated at 3 months post-intervention. Mediators will be assessed at mid-treatment (4 weeks). All youth will receive an 8-week internet-delivered pain self-management intervention (WebMAP). Following the recommended Common Data Elements for self-management three self-management processes are measured including patient activation, pain self-efficacy, and self-management skills, and patient-reported outcomes of health (global health, fatigue) and pain (pain symptoms, pain-related disability). Positive and negative affect and executive function are assessed as potential mediators. Sleep deficiency is comprehensively assessed with subjective measures, daily sleep logs, and ambulatory actigraphy monitoring to measure disrupted sleep, amount of sleep, sleep quality, and insomnia symptoms.
A stethoscope head cover configured to envelop a head of a stethoscope includes a cover member with a cavity therein. The cover member includes first and second openings. The first opening has a size sufficient to slidably engage a cord associated with the head of the stethoscope, and the second opening has a size sufficient to allow the head of the stethoscope to be extended therethrough. A stethoscope head cover with a cavity therein and a first opening having a size sufficient to allow the head of the stethoscope to be extended therethrough. The head cover can further include a biocidal environment within the cavity of the cover member. A method of sanitizing a stethoscope head includes providing a stethoscope head cover having a biocidal environment within a cavity of the stethoscope, and engaging a stethoscope head with the stethoscope head cover.
FIELD: medicine, pharmacy. SUBSTANCE: agent is an antibiotic made as a tablet covered by envelope. Core comprises roxithromycin and accessory substances: corn starch, sodium croscarmellose, aerosil, poly- vinylpyrrolidone, polyethylene polyhydroxypropylene glycol, hydroxypropylcellulose, talc, magnesium stearate and microcrystalline cellulose. Envelope comprises sucrose, titanium dioxide, propylene glycol and hydroxypropylmethylcellulose in the definite ratio of components of tablet. Agent is effective as an antibiotic and provides good, complete absorption. EFFECT: valuable medicinal properties of agent. 4 dwg, 7 tbl
This invention provides a cosmetic adhesive patch. It possesses a satisfactory adhesive force on a certain level. The patch can contain a vitamin irrespective of whether the vitamin is water-soluble or lipid-soluble. Even though the vitamin is, in particular vitamin C, the patch can inhibit the vitamin from suffering oxidation or hydrolytic deterioration and stably contain the vitamin C without causing gel deterioration. It also provides a method of using the cosmetic adhesive patch by which vitamin C can be effectively transferred from the cosmetic adhesive patch and absorbed in the skin. The package contains the cosmetic adhesive patch. The characteristic of the cosmetic adhesive patch is that it comprises a tacky polyurethane gel which has hydrophilic alkylene oxide segments and hydrophobic alkylene oxide segments. Therefore, most of or all of the segments are liquid at ordinary temperature. Finally, a vitamin incorporated therein.
BACKGROUND: Although albuminuria is the gold standard for defining chronic kidney disease (CKD), total proteinuria has also been widely used in real-world clinical practice. Moreover, the superiority of the prognostic performance of albuminuria over proteinuria in patients with CKD remains inconclusive. Therefore, we aimed to compare the predictive performances of albuminuria and proteinuria in these patients.
METHODS: From the Korean Cohort Study for Outcome in Patients with CKD we included 2099 patients diagnosed with CKD grades 1-5 who did not require kidney replacement therapy. We measured the spot urine albumin:creatinine ratio (mACR) and protein:creatinine ratio (PCR) and estimated the ACR (eACR) using the PCR. Kidney failure risk equation (KFRE) scores were calculated using the mACR, PCR and eACR. The primary outcome was the 5-year risk of kidney failure with replacement therapy (KFRT).
RESULTS: The eACR significantly underestimated mACR in patients with low albuminuria levels. The time-dependent area under the receiver operating characteristics curve showed excellent predictive performance for all KFRE scores from the mACR, PCR and eACR. However, eACR was inferior to mACR based on the continuous net reclassification index (cNRI) and integrated discrimination improvement index (IDI) in all CKD cause groups, except for the group with an unclassified aetiology. Moreover, the cNRI and IDI statistics indicated that both eACR and PCR were inferior to mACR in patients with low albuminuria (<30 mg/g). Conversely, the predictive performance of PCR was superior in severe albuminuria and nephrotic-range proteinuria, in which the IDI and cNRI of the PCR were greater than those of the mACR.
CONCLUSIONS: The mACR, eACR and PCR showed excellent performance in predicting KFRT in patients with CKD. However, eACR was inferior to mACR in patients with low albuminuria, indicating that measuring rather than estimating albuminuria is preferred for these patients.
CHI-101. Participants will drink one 7.0g CHI-101 powder sachet mixed into 16oz of water twice daily.
Pre-term and term born infants with corrected gestational age between term age and 24 months with radiologically-confirmed acute unilateral or bilateral brain lesions, including perinatal stroke, neonatal hemorrhagic or thrombotic stroke, involving the motor cortex and/or subcortical structures, and intracranial hemorrhage, involving the motor cortex and/or subcortical white matter, or periventricular leukomalacia. Parents/legal guardians able to attend study visits at the University of Wisconsin-Madison.
Live body weight (LBW) is one of the most important parameters for supervising the growth and development of livestock. The yak (Bos grunniens) is a special species of cattle that lives on the Qinghai-Tibetan Plateau. Yaks are more untamed than regular cattle breeds, so it is more challenging to measure their LBW. In this study, YOLOv8 yak detection and LBW estimation models were used to automatically estimate yak LBW in real time. First, the proper posture (normal posture) and individual yak identification was confirmed and then the YOLOv8 detection model was used for LBW estimation from 2-dimensional images. Yak LBW was estimated through yak body parameter extraction and a simple linear regression between the estimated yak LBW and the actual measured yak LBW. The results showed that the overall detection performance for normal yak posture was described by precision, recall, and mean average precision 50 (mAP50) indicators, reaching 81.8%, 86.0%, and 90.6%, respectively. The best yak identification results were represented by precision, recall, and mAP50 values of 97.8%, 96.4%, and 99.0%, respectively. The yak LBW estimation model achieved better results for the 12-mo-old yaks with shorter hair, with values for R2, root mean square error, mean absolute percentage error, and multiple R of 0.96, 2.43 kg, 1.69%, and 0.98, respectively. The results demonstrate that yak LBW can be estimated and monitored in real time using this approach. This study has the potential to be used for daily yak LBW monitoring in an unstressed manner and to save considerable labor resources for large-scale livestock farms. In the future, to reduce the limitations caused by the impacts of yak hair and light condition, datasets of dairy cows and yaks of different ages will be used to improve and generalize the model.
An anion crystal eye mask belongs to the fields of material preparation, daily chemical industry, cosmetics, fine chemical industry and the like. The negative ion crystal eye mask consists of two parts, namely an eye mask film and an eye mask liquid. The eye adhesive film is added with natural collagen, natural pearl nano powder and negative ion additive components, so that the effects of activating cells, promoting essence absorption and supplementing collagen required by skin are achieved. The eye patch adhesive film is crescent in shape and can be well attached to an eye curve structure, and in addition, the dense grid on the surface of the eye patch adhesive film is convexly designed, so that a space is provided for fully storing eye patch liquid. The eye patch liquid is added with eye patch essence, anion additive and coconut shell active carbon component. Therefore, the anion crystal eye mask can quickly replenish water and eliminate eye fatigue in a short time, and achieves the effects of reducing edema and relieving eye wrinkles and dark circles.
Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during your operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
This study intends to use the basic information and blood routine of schistosomiasis patients to establish a machine learning model for predicting liver fibrosis. We collected medical records of Schistosoma japonicum patients admitted to a hospital in China from June 2019 to June 2022. The method was to screen out the key variables and six different machine learning algorithms were used to establish prediction models. Finally, the optimal model was compared based on AUC, specificity, sensitivity and other indicators for further modeling. The interpretation of the model was shown by using the SHAP package. A total of 1049 patients' medical records were collected, and 10 key variables were screened for modeling using lasso method, including red cell distribution width-standard deviation (RDW-SD), Mean corpuscular hemoglobin concentration (MCHC), Mean corpuscular volume (MCV), hematocrit (HCT), Red blood cells, Eosinophils, Monocytes, Lymphocytes, Neutrophils, Age. Among the 6 different machine learning algorithms, LightGBM performed the best, and its AUCs in the training set and validation set were 1 and 0.818, respectively. This study established a machine learning model for predicting liver fibrosis in patients with Schistosoma japonicum. The model could help improve the early diagnosis and provide early intervention for schistosomiasis patients with liver fibrosis.
Endoscopic ultrasound (EUS) guided fine needle aspiration (FNA) and fine needle biopsy (FNB) are the standard methods for obtaining tissue samples from tumours of the pancreas. The diagnostic accuracy by strict criteria is around 75-80%. A non diagnostic sample causes delay and the need for a repeat procedure. To date no significant difference has been found between standard FNA and standard FNB needles. A novel opposing bevel design (SharkCore) needle for FNB may provide better diagnostic performance. The aim of this study is to compare the performance of a standard needle and the Sharkcore needle. Patients attending for routine biopsy of a suspected pancreatic tumour will be invited to participate. All participants will have 3 samples taken with each needle. The samples from each needle will be processed and reported separately with the pathologists blinded as to the report from the other needle. Following the procedure participants will be observed as normal in the recovery area and allowed home later. Further study participation is limited to 1 telephone call at 7 days. Participants will be asked if they have developed any new symptoms since the procedure and whether they have had to seek medical attention for this.The risks of the study procedure are the same as those of a non study procedure. Both needle types are in routine use in our unit. The study will be performed in the endoscopy unit of the Freeman hospital. The study is funded by a grant from Medtronic the company who make the Sharkcore needle. The study is planned to recruit 108 participants over 10 months with a further 6 months of follow up. If the new needle is found to perform better its routine use will potentially reduce the delay experienced by patients as well as the cost incurred by repeat procedures.
Prepare Technetium Tc 99m Succimer Injection according to the following procedure using asceptic technique:

  1. Wear waterproof gloves.
  2. Place the kit vial in lead shielding and disinfect the stopper (allow disinfectant to dry).
  3. Use a sterile syringe to transfer 5 mL sodium pertechnetate Tc 99m injection obtained from a technetium Tc 99m generator with a maximum activity of 1,480 MBq (40 mCi) to the vial. The volume of sodium pertechnetate Tc 99m injection may be adjusted to 5 mL prior to adding to the kit vial using 0.9% sodium chloride injection, USP.
  4. Use the same syringe to withdraw the appropriate gas volume from the vial for pressure compensation.
  5. Lightly shake the vial to completely dissolve the powder. Ensure the stopper is well moistened.
  6. Incubate the vial for 10 minutes at controlled room temperature 20°C to 25°C (68°F to 77°F).
  7. Measure the product activity in a dose calibrator; complete the radiolabeled product vial label and affix to the vial shield.
  8. Check radiochemical purity according to the method in 2.5 Radiochemical Purity Determination [see Dosage and Administration (2.5)].
  9. Use Technetium Tc 99m Succimer Injection within 4 hours and store at controlled room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Studying tumor immune microenvironment (TIME) is pivotal to understand the mechanism and predict the outcome of cancer immunotherapy. Systems biology mathematical models can consider and control various factors of TIME and therefore explore the anti-tumor immune response meticulously. However, the role of tumor vasculature in the recruitment of T cells and the mechanism of T cell migration through TIME have not been studied comprehensively. In this work, we developed a hybrid discrete-continuum multi-scale model to study TIME. The mathematical model includes angiogenesis and T cell recruitment via tumor vasculature. Moreover, solid tumor growth, vascular growth and remodeling, interstitial fluid flow, hemodynamics, and blood rheology are all considered in the model. In addition, different aspects of T cells, including their migration, proliferation, subtype conversion, and interaction with tumor cells are thoroughly included. The model reproduces spatiotemporal distribution of tumor infiltrating T cells that mimics histopathological patterns. Furthermore, TIME model robustly recapitulates different phases of tumor immunoediting. We also examined a number of biomarkers to predict the outcome of immune checkpoint blockade (ICB) treatment. The results demonstrated that although tumor mutational burden (TMB) may predict non-responders to ICB, a combination of different biomarkers is essential to predict the majority of the responders. Based on our results, the ICB response rate varies significantly from 28 to 89% depending on the values of different parameters, even in the cases with high TMB.
The behavior stage was determined by applying the "Stages of Change Scale" (SCS) form to the women participating in the control group. The pre-test data of the women participating in the control group were applied via the Participant Identification Form, FNDT, SCS, BCPS/EFS and DBS and the FNDT form to those who continued to smoke during pregnancy. Post-test data from women in the control group were collected with the postpartum part of the Participant Identification Form at 4 weeks postpartum, FNDT, SCS, BCPS/EFS and DBS for smokers.